Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/04/2010US20100280033 Pyrazole Derivatives
11/04/2010US20100280031 Lipid formulation of apoptosis promoter
11/04/2010US20100280030 2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumours
11/04/2010US20100280029 Novel compounds
11/04/2010US20100280027 Pharmaceutical compounds
11/04/2010US20100280026 Compositions useful as inhibitors of protein kinases
11/04/2010US20100280018 Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors
11/04/2010US20100280012 Azaazulene compounds
11/04/2010US20100280008 Aurora kinase modulators and method of use
11/04/2010US20100280006 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
11/04/2010US20100280003 Combinations of jak inhibitors
11/04/2010US20100280001 Imidazoquinolines with immuno-modulating properties
11/04/2010US20100279995 Novel Ansamycin Derivatives
11/04/2010US20100279994 Ansamycin Formulations and Methods of Use Thereof
11/04/2010US20100279992 Use of lanostane and poria extract in treating cachexia
11/04/2010US20100279990 Antiproliferative compounds, compositions and methods of use
11/04/2010US20100279986 Heterocyclic derived metalloprotease inhibitors
11/04/2010US20100279977 Compositions and methods for treating cancer
11/04/2010US20100279976 Use of artemisinin and its derivatives in cancer therapy
11/04/2010US20100279975 Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
11/04/2010US20100279971 Antifolate compounds for the treatment of melanoma
11/04/2010US20100279967 Compositions and methods for treating cancer
11/04/2010US20100279966 Compositions and methods for treating cancer
11/04/2010US20100279965 Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
11/04/2010US20100279964 Angular Pyranocoumarins, Process for Preparation and Uses Thereof
11/04/2010US20100279963 Dicarbonyl derivatives and methods of use
11/04/2010US20100279961 Pharmaceutical composition having a trihydroxy-chromenone derivative
11/04/2010US20100279958 Compounds and methods for inhibiting selectin-mediated function
11/04/2010US20100279950 Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods
11/04/2010US20100279949 Process for preparing recombinant heterocarpine
11/04/2010US20100279948 EPIGENETIC MODIFICATIONS AT TNFalpha AS BIOMARKERS FOR SENSITIVITY TO SMAC MIMETIC-INDUCED APOPTOSIS
11/04/2010US20100279947 Modifications of apoptin
11/04/2010US20100279944 Suppression and treatment of neuropathic pain
11/04/2010US20100279937 Method of Inhibiting Angiogenesis, Tumorigenesis and Cathepsin Activity
11/04/2010US20100279933 Vegf antagonist formulations
11/04/2010US20100279932 Binding constructs and methods for use thereof
11/04/2010US20100279927 Growth factor complex
11/04/2010US20100279923 Therapeutic application of kazal-type serine protease inhibitors
11/04/2010US20100279922 Melanocortin Receptor Ligands
11/04/2010US20100279919 Compositions comprising human integrin-linked kinase-sirna and methods of use thereof
11/04/2010US20100279918 Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
11/04/2010US20100279406 Alteration of tumor growth using zinc finger proteins
11/04/2010US20100279327 Method of treating diseases with parp inhibitors
11/04/2010US20100278997 Preparation for restenosis prevention
11/04/2010US20100278947 Methods for modulating Eicosanoid metabolism
11/04/2010US20100278945 Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
11/04/2010US20100278941 Enhanced erythropoiesis and iron metabolism
11/04/2010US20100278937 Compositions and methods to prevent and/or treat cancer with pa-card
11/04/2010US20100278935 Immune System Modulator Formulation
11/04/2010US20100278933 Kinase inhibitor compounds
11/04/2010US20100278928 Polymer micelles containing anthracylines for the treatment of cancer
11/04/2010US20100278925 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof
11/04/2010US20100278924 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
11/04/2010US20100278921 Solid oral formulation of abt-263
11/04/2010US20100278919 Dendritic cell targeting compositions and uses thereof
11/04/2010US20100278911 Controlled release preparation
11/04/2010US20100278905 Stabilized lipid formulation of apoptosis promoter
11/04/2010US20100278901 Compositions and methods of making rapidly dissolving ionically masked formulations
11/04/2010US20100278896 Solid compositions
11/04/2010US20100278874 Reagents and methods for cancer treatment and prevention
11/04/2010US20100278873 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
11/04/2010US20100278872 Medicaments and methods for treating mesothelioma
11/04/2010US20100278871 Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
11/04/2010US20100278863 Reoviruses
11/04/2010US20100278851 Ctl inducer composition
11/04/2010US20100278850 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
11/04/2010US20100278849 Prostatic acid phosphatase antigens
11/04/2010US20100278848 Tumor antigen bfy3 for prevention and/or treatment of cancer
11/04/2010US20100278844 Cancer Marker and Therapeutic Target
11/04/2010US20100278843 Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
11/04/2010US20100278842 Anti-ephb2 antibodies and methods using same
11/04/2010US20100278841 DOWN-REGULATION OF MORTALIN BY siRNA
11/04/2010US20100278838 Epha2 monoclonal antibodies and methods of use thereof
11/04/2010US20100278837 Compositions And Methods For Reducing Cancer And Inflammation
11/04/2010US20100278833 Thiophene-imidazopyridines
11/04/2010US20100278832 Anti-bst2 antibody
11/04/2010US20100278830 Methods and systems for multi-antibody therapies
11/04/2010US20100278829 Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members
11/04/2010US20100278828 Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
11/04/2010US20100278824 Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
11/04/2010US20100278822 Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
11/04/2010US20100278821 N-cadherin: target for cancer diagnosis and therapy
11/04/2010US20100278820 Reagents that bind ccx-ckr2
11/04/2010US20100278818 Antibody specific for the Tn antigen for the treatment of cancer
11/04/2010US20100278815 Humanized Monoclonal Antibodies to Hepatocyte Growth Factor
11/04/2010US20100278811 Vasculostatic agents and methods of use thereof
11/04/2010US20100278810 Methods of Modulating Angiogenesis
11/04/2010US20100278802 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
11/04/2010US20100278801 Compositions comprising optimized her1 and her3 multimers and methods of use thereof
11/04/2010US20100278797 Pharmaceutical Composition and Method for Regulating Abnormal Cellular Proliferation
11/04/2010US20100278779 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
11/04/2010US20100278776 Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
11/04/2010US20100278775 Plant Bioreactor For The Production Of Interleukin-24 Cytokine
11/04/2010US20100278773 Chimeric flavivirus vaccines
11/04/2010US20100278772 Dna methylation markers and methods of use
11/04/2010US20100278744 Preparation for restenosis prevention
11/04/2010US20100278741 Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same
11/04/2010US20100278739 Targeted, nir imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
11/04/2010US20100278737 Organic-inorganic hybrid particles containing contrast agent
11/04/2010US20100278736 FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy
1 ... 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 ... 2211